Form 4: Xenetic Biosciences Director Acquires Stock Options

Grigory G. Borisenko, a director at Xenetic Biosciences, Inc., acquired 2,500 stock options on December 11, 2024.

Summary

• Grigory G. Borisenko, a director of Xenetic Biosciences, Inc., has reported a transaction involving the acquisition of stock options.
• On December 11, 2024, Borisenko acquired 2,500 stock options with an exercise price of $4.24.
• These options vest 100% on the twelve-month anniversary of the grant date, which is December 11, 2025.
• The options expire on December 11, 2034.
• The transaction was reported on December 13, 2024.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a routine transaction of stock options being granted to a director. It is neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting period of 12 months is fairly standard for such grants.
• The 10-year expiration period is also typical for stock options.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Xenetic Biosciences, director, XBIO